NICE

The National Institute for Health and Care Excellence (NICE) is an executive non-departmental public body sponsored by Department of Health in the United Kingdom, which publishes guidelines on the use of health technologies within the NHS (such as the use of new and existing medicines, treatments and procedures), clinical practice (guidance on the appropriate treatment and care of people with specific diseases and conditions), guidance for public sector workers on health promotion and ill-health avoidance, guidance for social care services and users. These appraisals are based primarily on evaluations of efficacy and cost–effectiveness in various circumstances. NICE was established in an attempt to end the so-called postcode lottery of healthcare in England and Wales, where treatments that were available depended upon the NHS Health Authority area in which the patient happened to live, but it has since acquired a high reputation internationally as a role model for the development of clinical guidelines. One aspect of this is the explicit determination of cost–benefit boundaries for certain technologies that it assesses. NICE also plays an important role in pioneering technology assessment in other healthcare systems through NICE International, established in May 2008 to help cultivate links with foreign governments.


NICE would welcome further discussions about access to spinal muscular atrophy drug nusinersen

Draft guidance does not recommend nusinersen, also called Spinraza and made by Biogen, for routine use on the NHS because of uncertainties over its long-term effectiveness and its extremely high cost. The committee concluded that, based on its list price, the cost-effectiveness estimates for nusinersen ranged between £400,000 and £600,000 […]


Launch of new master’s degree in Evaluation of Health Care Interventions and Outcomes

The MSc, which takes 2 years to complete, will offer skills in health services research, health economics, outcomes research, and health policy. It is aimed at professionals from a wide range of backgrounds, including the medical professions, pharmaceutical and medical devices industries, healthcare management, government and non-governmental organisations. Professor Elias […]


Antibiotics should be restricted for COPD

  These draft recommendations come as NICE publishes draft antimicrobial prescribing guidance and a separate update to its 2010 clinical guideline on diagnosing and managing COPD in over 16s. The draft antimicrobial guidance recommends that antibiotics should be offered to people who have a severe flare up of symptoms, also known as […]


NICE backed award for physiotherapist helping to improve patients’ quality of life

A physiotherapist who developed a specialist rehabilitation programme for patients with lung disease has been honoured. Laura McNeillie received the NICE into Action award, at the Chief Allied Health Professionals Officer’s awards for developing a new pulmonary rehabilitation programme tailored for patients with interstitial lung disease. Laura’s work as a […]


Adding pertuzumab to existing treatments after surgery for early breast cancer not cost effective, says NICE in draft guidance

Continuing or starting with pertuzumab alongside trastuzumab and chemotherapy after surgery for women with HER2 positive cancer may not extend their life and is not cost effective, the draft guidance says. NICE already recommends pertuzumab (also called Perjeta and made by Roche), given with trastuzumab and chemotherapy, for treating early […]


Adding pertuzumab to existing treatments after surgery for early breast cancer not cost effective, says NICE in draft guidance

Continuing or starting with pertuzumab alongside trastuzumab and chemotherapy after surgery for women with HER2 positive cancer may not extend their life and is not cost effective, the draft guidance says. NICE already recommends pertuzumab (also called Perjeta and made by Roche), given with trastuzumab and chemotherapy, for treating early […]


Long term benefit of neuroblastoma treatment is too uncertain, says NICE

Evidence suggests dinutuximab beta (Qarziba, EUSA Pharma) could increase overall survival compared with current treatment, but there is still substantial uncertainty about its long-term benefits. Because dinutuximab beta has promising clinical benefit, the NICE appraisal committee would like to recommend it for managed access in the Cancer Drugs Fund (CDF). […]